3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
3
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
43
Breast
25
Gastrointestinal
16
Tumor-Agnostic
13
Genitourinary
13
Thoracic
11
Sarcoma
10
Other solid neoplasm
8
Classical hematology
6
Head & Neck
4
CNS
4
Lymphoid
3
NET
1
Myeloid
1
Endocrine
1
Dermatologic
1
Conditions
Thymoma
1
Neuroendocrine Tumors
1
Mesothelioma
1
Interventions
Everolimus
19
lutetium Lu 177 dotatate
8
Octreotide
8
lanreotide
7
pasireotide
6
Temozolomide
6
Sunitinib
6
pembrolizumab
5
gallium Ga 68 dotatate
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
olaparib
×
NET
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled